Try Alerts Free   |   Login
Health Care › Biological Products (No Diagnostic Substances)

FATE Price Correlated With Financials For Fate Therapeutics

Free historical financial statements for Fate Therapeutics Inc. See how revenue, income, cash flow, and balance sheet financials have changed over 35 quarters since 2014. Compare with FATE stock chart to see long term trends.

FATE Stock Compared to Quarterly

FATE Income Statement

Revenue, Net:14981000
Revenue Per Share:0.1542
Selling, General & Admin Expense:21555000
Research & Development Expense:79817000
Total Operating Expenses:101372000
Operating Income:-86391000
Net Income:-83563000
Earnings Per Share, Basic:-0.86
Shares Outstanding, Basic Avg:97170443

FATE Cash Flow

Operating Activities Net Income:
Depreciation, Depletion & Amortization:3193000
Change in Accounts Receiveable:-2903000
Net Cash from Operations:-55047000
Net Cash from Operations Per Share:-0.5665
Net Cash from Financing Activities:1487000
Property, Plant & Equipment Purchases:8676000
Net Cash from Investing Activities:80378000
Net Change in Cash & Equivalents:26818000

FATE Balance Sheet

Cash and Cash Equivalents:97320000
Accounts Receivable, Net:10223000
Total Current Assets:535329000
Property, Plant & Equipment, Net:109118000
Total Assets:749349000
Accounts Payable:9593000
Total Short-Term Liabilities:103938000

Insider Trading

 
Change
Value
Transaction
SEC Form 4
MENDLEIN JOHN   Director
124,679 sh at $6
$698,138
Buy

Major Holders (from 13F filings)

Investment Type
Change
Value (x$1000)
increase or decrease
Redmile Group, LLC
12,957,222 sh
 
$290,371
Ark Investment Management LLC
11,655,833 sh
182,178 sh
2%
$261,207
-$3,834
Capital World Investors
8,231,312 sh
-988 sh
0%
$184,464
-$19,532
Blackrock Inc.
7,917,421 sh
501,445 sh
7%
$177,428
-$6,341
Vanguard Group Inc
7,814,980 sh
57,040 sh
1%
$175,133
-$17,108
State Street Corp
4,382,634 sh
-887,501 sh
-17%
$98,215
-$32,379
Bellevue Group Ag
3,746,086 sh
196,000 sh
6%
$83,950
-$4,022
Johnson & Johnson
3,379,064 sh
 
$75,725
Price T Rowe Associates Inc /Md/
3,141,653 sh
-1,841,850 sh
-37%
$70,405
-$53,086
Artal Group S.A.
2,600,000 sh
 
$58,266
Pictet Asset Management SA
2,150,276 sh
48,115 sh
2%
$48,188
-$3,904
Casdin Capital, LLC
2,050,000 sh
-50,000 sh
-2%
$45,941
-$6,097
JPMorgan Chase & Co
2,033,203 sh
35,796 sh
2%
$45,564
-$3,932
Geode Capital Management, LLC
1,499,680 sh
34,002 sh
2%
$33,607
-$2,712
FMR LLC
1,462,065 sh
48,206 sh
3%
$32,764
-$2,271
Janus Henderson Group Plc
1,424,726 sh
-10,787 sh
-1%
$31,929
-$3,643
Westfield Capital Management Co Lp
1,391,217 sh
170,896 sh
14%
$31,177
-$16,135
Morgan Stanley
1,369,721 sh
-254,548 sh
-16%
$30,697
-$9,553
Deep Track Capital, LP
1,311,113 sh
-706,892 sh
-35%
$29,382
-$20,624
Sumitomo Mitsui Trust Holdings, Inc.
1,288,858 sh
18,293 sh
1%
$28,883
-$2,602

Data imported from Fate Therapeutics Inc SEC filings. Check original filings before making any investment decision.